KR900014385A - 제약학적 치료 - Google Patents

제약학적 치료 Download PDF

Info

Publication number
KR900014385A
KR900014385A KR1019900002767A KR900002767A KR900014385A KR 900014385 A KR900014385 A KR 900014385A KR 1019900002767 A KR1019900002767 A KR 1019900002767A KR 900002767 A KR900002767 A KR 900002767A KR 900014385 A KR900014385 A KR 900014385A
Authority
KR
South Korea
Prior art keywords
compound
composition
formula
administered
pro
Prior art date
Application number
KR1019900002767A
Other languages
English (en)
Other versions
KR0143410B1 (ko
Inventor
리차드 보이드 맬컴
섯튼 데이빗
Original Assignee
데이빗 로버츠
비이참 그루우프 피이엘시이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10652653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900014385(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 데이빗 로버츠, 비이참 그루우프 피이엘시이 filed Critical 데이빗 로버츠
Publication of KR900014385A publication Critical patent/KR900014385A/ko
Application granted granted Critical
Publication of KR0143410B1 publication Critical patent/KR0143410B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

제약학적 치료
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 일반식 (A) :
    의 화합물 또는 전-의약(pro-drug), 또는 그들중 하나의 제약학적으로 허용가능한 염, 포스페이트 에스테르 및/또는 아실 유도체, 및 제약학적으로 허용가능한 담체로 구성되는, 포유동물의 B형 비루스성 간염 전염을 치료하는데 사용되는 제약학적 조성물.
  2. 제 1항에 있어서, 투여되는 화합물이 일반식(A)의 펜시클로비르(penciclovir)인 조성물.
  3. 제 1항에 있어서, 투여되는 화합물이 일반식(A) 화합물의 나트륨 염 수화물인 조성물.
  4. 제 3항에 있어서, 비경구적 투여에 적합한 수성 배합물인 조성물.
  5. 제 1항에 있어서, 투여되는 화합물이 일반식(B) :
    (여기서, X는 C1-6알콕시, NH2또는 수소임)를 갖는 일반식(A) 화합물의 전-의약 또는 제 1항에서 일반식 (A)에 대해 정의된 그들의 염 또는 유도체인 조성물.
  6. 제 5항에 있어서, 일반식(B)의 전-의약 화합물이 X가 수소이고 두개의 OH기가 아세틸 유도체의 형인 팜시클로비르(famciclovir)인 조성물.
  7. 제 6항에 있어서, 경구 투여에 적합한 조성물.
  8. 제 1항에 있어서, 투여된 화합물이 50㎎-1g단위 투여량인 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900002767A 1989-03-03 1990-03-03 B형 비루스성 간염치료용 제약학적 조성물 KR0143410B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8904855.7 1989-03-03
GB898904855A GB8904855D0 (en) 1989-03-03 1989-03-03 Pharmaceutical treatment

Publications (2)

Publication Number Publication Date
KR900014385A true KR900014385A (ko) 1990-10-23
KR0143410B1 KR0143410B1 (ko) 1998-07-15

Family

ID=10652653

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900002767A KR0143410B1 (ko) 1989-03-03 1990-03-03 B형 비루스성 간염치료용 제약학적 조성물

Country Status (18)

Country Link
US (1) US6136813A (ko)
EP (1) EP0388049B1 (ko)
JP (1) JP2513519B2 (ko)
KR (1) KR0143410B1 (ko)
AT (1) ATE122562T1 (ko)
AU (1) AU628137B2 (ko)
CA (1) CA2011238C (ko)
CY (1) CY1870A (ko)
DE (1) DE69019404T2 (ko)
DK (1) DK0388049T3 (ko)
ES (1) ES2072386T3 (ko)
GB (1) GB8904855D0 (ko)
HK (1) HK116795A (ko)
HU (1) HU205715B (ko)
IE (1) IE67125B1 (ko)
IL (1) IL93594A (ko)
LV (1) LV10923B (ko)
ZA (1) ZA901572B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326177D0 (en) * 1993-12-22 1994-02-23 Smithkline Beecham Plc Pharmaceuticals
US6124304A (en) * 1993-10-05 2000-09-26 Smithkline Beecham Plc Penciclovir for the treatment of zoster associated pain
WO1995022330A1 (en) * 1994-02-17 1995-08-24 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
DE69629188T2 (de) 1995-04-24 2004-04-22 Novartis International Pharmaceutical Ltd. Verwendung von (r)-penciclovirtriphosphat zur herstellung eines arzneimittels zur behandlung von viruserkrankungen
WO1998023285A1 (en) * 1996-11-29 1998-06-04 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis b
US5939423A (en) * 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
AUPO912997A0 (en) * 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
US6288033B1 (en) 1998-09-25 2001-09-11 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir
ID29471A (id) * 1998-11-02 2001-08-30 Triangle Pharmaceuticals Inc Terapi kombinasi untuk mengobati virus hepatitis b
AU2013257951A1 (en) 2012-05-11 2015-01-22 Akron Molecules Ag Use of compounds for the treatment of pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4230708A (en) * 1977-10-20 1980-10-28 Stichting Rega V.Z.W. Therapeutic application of (S) -or (RS)-9-(2, 3-dihydroxypropyl) adenine for use as antiviral agents
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
US4556659A (en) * 1982-08-09 1985-12-03 Syntex (U.S.A.) Inc. Substituted 9-(1-0- or 3-0-monosubstituted or 1,3-Di-0-substituted propoxymethyl)-purines as antiviral agents
US4649140A (en) * 1982-10-14 1987-03-10 Burroughs Wellcome Co. Purine derivatives
US5059604A (en) * 1982-10-14 1991-10-22 Burroughs Wellcome Co. 2-amino purine derivatives
DE3485225D1 (de) * 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
IL73682A (en) * 1983-12-20 1991-08-16 Medivir Ab Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation
DE3582399D1 (de) * 1984-09-20 1991-05-08 Beecham Group Plc Purin-derivate und ihre pharmazeutische verwendung.
SE8406538D0 (sv) * 1984-12-21 1984-12-21 Astra Laekemedel Ab Novel derivatives of purine
EP0216459B1 (en) * 1985-07-27 1990-05-16 Beecham Group Plc 9-substituted guanine monohydrates
SE8602981D0 (sv) * 1986-07-04 1986-07-04 Astra Laekemedel Ab Novel medicinal use
HU196038B (en) * 1987-08-07 1988-09-28 Mta Koezponti Kemiai Kutato In Process for producing antiherpetic pharmaceutics for external use, containing 5-isopropyl-2'-beta-deoxy-uridine
SE8801729D0 (sv) * 1988-05-06 1988-05-06 Astra Ab Purine derivatives for use in therapy
GB8823320D0 (en) * 1988-10-05 1988-11-09 Nycomed As Chemical compounds

Also Published As

Publication number Publication date
LV10923A (lv) 1995-12-20
JP2513519B2 (ja) 1996-07-03
EP0388049B1 (en) 1995-05-17
US6136813A (en) 2000-10-24
AU5060090A (en) 1990-11-01
AU628137B2 (en) 1992-09-10
HU205715B (en) 1992-06-29
LV10923B (en) 1996-06-20
GB8904855D0 (en) 1989-04-12
IL93594A0 (en) 1990-12-23
IE67125B1 (en) 1996-03-06
CY1870A (en) 1996-04-05
DE69019404D1 (de) 1995-06-22
HUT53522A (en) 1990-11-28
ZA901572B (en) 1991-03-27
EP0388049A3 (en) 1991-11-06
ATE122562T1 (de) 1995-06-15
IE900733L (en) 1990-09-03
IL93594A (en) 1995-05-26
DK0388049T3 (da) 1995-06-06
EP0388049A2 (en) 1990-09-19
CA2011238C (en) 2000-03-28
HK116795A (en) 1995-07-21
CA2011238A1 (en) 1990-09-03
ES2072386T3 (es) 1995-07-16
JPH02275821A (ja) 1990-11-09
KR0143410B1 (ko) 1998-07-15
DE69019404T2 (de) 1995-10-12
HU901252D0 (en) 1990-05-28

Similar Documents

Publication Publication Date Title
KR900701815A (ko) 피리미딘 유도체
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
KR920008026A (ko) 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
ATE4903T1 (de) 1-, 6- und 2-substituierte 1-carba-2-penem-3carbons[ure, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
KR890016966A (ko) 신규 항바이러스제
KR900014385A (ko) 제약학적 치료
FI940696A0 (fi) Uudet pyratsiinijohdannaiset, niiden valmistus ja käyttö
ES2108240T3 (es) Derivados de tiosemicarbazona de 2-formilpiridina, su preparacion y su uso como agentes antitumor.
KR890014107A (ko) 백금 화학 요법약제
ATE73449T1 (de) 2-piperazinyl-2-oxo-aethylensubstituierte flavonoid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammenstellungen.
ES2028917T3 (es) Un procedimiento para preparar una composicion farmaceutica inyectable estable.
KR880007080A (ko) 제약학적 생성물
DK160686A (da) Tri- og tetracycliske forbindelser
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
KR900014397A (ko) 티에노-트리아졸로-디아제핀 술포닐 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR900701814A (ko) 뉴클레오사이드 동족체
KR890002128A (ko) 실비빈의 가용성 유도체, 그것의 제조방법 및 그것을 함유하는 제약학적 조성물
KR890009922A (ko) 아테롬성 동맥경화증 치료제로서의 dl-5-[(2-벤질-3,4-디하이드로-2H-벤조피란-6-일)메틸]티아졸리딘-2,4-디온
KR880004810A (ko) 소화성 궤양 치료제
KR910000777A (ko) 정균 활성을 갖는 안트라사이클린 유도체
KR950008502A (ko) 3-또는4-클리코실옥시벤조피란 유도체 및 활성 성분으로서 이를 함유하는 알러지치료제
KR950032264A (ko) 7-글리코실옥시벤조피란 유도체 및 이를 활성 성분으로서 함유하는 항알레르기제
KR930021203A (ko) 죽상동맥경화 치료제로서의 독사조신의 히드록실화된 대사산물 및 유도체
KR980002033A (ko) 트리아졸 유도체 또는 그 염

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
J204 Request for invalidation trial [patent]
J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 19990305

Effective date: 20001130

LAPS Lapse due to unpaid annual fee